Acalabrutinib

ACP-196 is an experimental anticancer drug that is a selective Bruton tyrosine kinase (BTK) inhibitor. This kinase transmits signals from the B-cell receptor (BCR), so any inherited BTK mutation will lead to B-cell immune deficiency. Thus, BTK inhibitors targeting B-cell signaling have shown great promise for the treatment of chronic lymphocytic leukemia (CLL). AcChemicalbookalabrutinib is an experimental anticancer drugs, as well as a kind of selective bruton tyrosine kinase (BTK) inhibitors. This kinase transmits signals from the b cell receptor (BCR), so any mutation in the BTK gene leads to b cell immune deficiency. Therefore, BTK inhibitors targeting B-cell signaling show great potential in the treatment of chronic lymphocytic leukemia (CLL).